Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherry Bhalla

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Science Advances|November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implicationsSherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
Cancer Discovery|December 18, 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell ImmunotherapyRanjan Upadhyay, Jonathan A Boiarsky, Gvantsa Pantsulaia, et al.
JCO Precision Oncology|June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple MyelomaPaula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Blood Neoplasia|June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myelomaRudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Blood Advances|November 5, 2025
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid SuppressionJunia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Science Advances|November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implicationsSherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
Cancer Discovery|December 18, 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell ImmunotherapyRanjan Upadhyay, Jonathan A Boiarsky, Gvantsa Pantsulaia, et al.
JCO Precision Oncology|June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple MyelomaPaula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Blood Neoplasia|June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myelomaRudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Blood Advances|November 5, 2025
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid SuppressionJunia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, et al.
Pageof 3